CNNC (Cannonau) Institutional Ownership: 0.97% (As of Jun. 30, 2026)


What is Cannonau Institutional Ownership?

Cannonau CNNC Institutional Ownership is 0.97% as of Jun. 30, 2026.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cannonau's institutional ownership is 0.97%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cannonau's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cannonau's Float Percentage Of Total Shares Outstanding is 8.84%.

Cannonau Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Cannonau's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannonau Institutional Ownership Chart

Cannonau Historical Data

The historical data trend for Cannonau can be seen below:

2014-09-30 2014-10-31 2014-11-30 2014-12-31 2015-01-31 2015-02-28 2015-03-31 2015-04-30 2015-05-31 2015-06-30
Institutional Ownership 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97

Cannonau Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.97% mean?
Cannonau (CNNC) has a Institutional Ownership of 0.97% as of Jun. 30, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cannonau and its competitors.
Is Cannonau's Institutional Ownership too high?
Cannonau's current Institutional Ownership is 0.97%.
How does Cannonau's Institutional Ownership compare to KOAN and THCT?
Cannonau's Institutional Ownership of 0.97% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cannonau and its competitors. Cannonau's current Institutional Ownership is 0.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannonau stock overvalued right now?
Cannonau (CNNC) has a current Institutional Ownership of 0.97%. The current Institutional Ownership is 0.97%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Cannonau (CNNC), the current Institutional Ownership is 0.97% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cannonau Business Description

Address 937 Old Seneca Turnpike Road, Skaneateles, NY, USA, 13252-9318
Cannonau Corp is using cutting-edge nanotechnology plans to offer Cannabidiol (CBD) for improved bioavailability and maximum benefit. It believes that its formulas can be easily incorporated into a wide, offering customers an advantage when it counts.